<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04465916</url>
  </required_header>
  <id_info>
    <org_study_id>EYP001-201</org_study_id>
    <nct_id>NCT04465916</nct_id>
  </id_info>
  <brief_title>Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)</brief_title>
  <official_title>A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of Oral FXR Modulator EYP001a Combined With Nucleos(t)Ide Analogues (NA) in Virologically Suppressed Chronic Hepatitis B Patients to Improve Functional Cure Rates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enyo Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novotech (Australia) Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Synteract, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eurofins</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Enyo Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-centre, randomized, double-blind, placebo-controlled, Phase 2a&#xD;
      experimental study of oral FXR modulator EYP001a/placebo combined with NAs in virologically&#xD;
      suppressed CHB patients to improve functional cure rates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 49 eligible patients will be enrolled and randomized at approximately 14 study&#xD;
      sites. Patients will be randomized prior to study drug (EYP001a or placebo and NA)&#xD;
      administration on Day 1 in the ratio of 3:1 into 2 arms:&#xD;
&#xD;
        -  Experimental Arm: EYP001a Dose A QD + NA daily (37 patients)&#xD;
&#xD;
        -  Control Arm: Placebo + NA daily (12 patients)&#xD;
&#xD;
      The maximum total engagement duration for eligible patients in this study is up to 370 days:&#xD;
      90 days screening, 112 days (16 weeks) treatment period and 168 days (24 weeks) follow-up.&#xD;
&#xD;
      Patients enrolled in the study will be assessed as outpatients. Patient screening will occur&#xD;
      no more than 90 days prior to the Day 1 visit. Eligible patients will undergo further&#xD;
      assessments on Day 1 to qualify for study drug administration on Day 1.&#xD;
&#xD;
      The visits during the study are planned as below:&#xD;
&#xD;
        -  Screening visit: 12 weeks (90 days)&#xD;
&#xD;
        -  16 weeks treatment period:&#xD;
&#xD;
        -  Treatment Visit 1 (Week 1 [Day 1])&#xD;
&#xD;
        -  Treatment Visit 2 (Week 2 [Day 14 ±3 days])&#xD;
&#xD;
        -  Treatment Visit 3 (Week 4 [Day 28 ±3 days])&#xD;
&#xD;
        -  Treatment Visit 4 (Week 6 [Day 42 ±3 days])&#xD;
&#xD;
        -  Treatment Visit 5 (Week 8 [Day 56 ±3 days])&#xD;
&#xD;
        -  Treatment Visit 6 (Week 10 [Day 70 ± 3 days])&#xD;
&#xD;
        -  Treatment Visit 7 (Week 12 [Day 84 ± 3 days])&#xD;
&#xD;
        -  Treatment Visit 8 (Week 14 [Day 98 ± 3 days])&#xD;
&#xD;
        -  Treatment Visit 9 (Week 16 [Day 112±3 days])&#xD;
&#xD;
        -  24 weeks safety follow-up period:&#xD;
&#xD;
        -  Follow-up Visit 1 (Week 20 [Day 140 ±7 days])&#xD;
&#xD;
        -  Follow-up Visit 2 (Week 28 [Day 196 ±7 days])&#xD;
&#xD;
        -  Follow-up Visit 3 (Week 40 [Day 280 ±7 days]) Note: during follow-up patients are kept&#xD;
           on NA until the end of the trial: Week 40 (consolidation Phase).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 12, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Triple blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>HBsAg change</measure>
    <time_frame>16 weeks</time_frame>
    <description>Efficacy assessed as HBsAg change (Δ log10) from Day 1 to Week 16 of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBsAg responder rate change</measure>
    <time_frame>40 weeks</time_frame>
    <description>HBsAg responder rate (change from baseline ≥ 1.0 on the log10 scale) at Week 16 of treatment and Weeks 20, 28 and 40 of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg responder rate change</measure>
    <time_frame>40 weeks</time_frame>
    <description>HBsAg responder rate (change from baseline ≥ 0.5 on the log10 scale) at Weeks 12 and 16 of treatment and Weeks 20, 28 and 40 of follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg loss rate</measure>
    <time_frame>40 weeks</time_frame>
    <description>HBsAg loss rate (percent of patients with HBsAg &lt; lower limit of quantification [LLOQ]) at Week 16 of treatment and Weeks 20, 28 and 40 of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg loss rate</measure>
    <time_frame>40 weeks</time_frame>
    <description>HBsAg loss rate (Proportion of results that are Target Not Detected versus Target Detected) at Week 16 of treatment and Weeks 20, 28 and 40 of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate HBsAg</measure>
    <time_frame>40 weeks</time_frame>
    <description>Relapse rate HBsAg (percent of patients who became negative [HBsAg &lt; LLOQ], then increased with HBsAg &gt; LLOQ) at Week 16 of treatment period and Weeks 20, 28 and 40 during follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic failure rate</measure>
    <time_frame>40 weeks</time_frame>
    <description>Virologic failure rate (breakthrough)2 of HBV-DNA (% patients with a confirmed quantifiable HBV DNA increase of ≥ 1log10 HBV DNA copies/mL above LLOQ3) assessed at Week 16 of treatment period and Weeks 20, 28 and 40 during follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV-pgRNA change</measure>
    <time_frame>40 weeks</time_frame>
    <description>HBV-pgRNA change (Δ log10) from Day 1 to Weeks 4, 8, 12, 16 of treatment period and Week 40 of maintenance period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBcrAg change</measure>
    <time_frame>40 weeks</time_frame>
    <description>HBcrAg change (Δ log10) from Day 1 to Weeks 4, 8, 12, 16 of treatment period and Week 40 of maintenance period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg quantification</measure>
    <time_frame>40 weeks</time_frame>
    <description>HBeAg quantification for HBeAg pos patients and changes at Week 16 of treatment and Week 40 of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroscan VCTE change</measure>
    <time_frame>40 weeks</time_frame>
    <description>Fibroscan VCTE change from screening value to Weeks 16 and 40 or ET value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Adverse Events)</measure>
    <time_frame>40 weeks</time_frame>
    <description>Safety and Tolerability assessed as: AEs including serious adverse events [SAEs]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK (EYP001a/placebo blood dosage)</measure>
    <time_frame>16 weeks</time_frame>
    <description>PK assessed as:&#xD;
o Plasma concentration of EYP001a or any relevant active metabolites (as identified in an ongoing phase 1 study).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD : C4</measure>
    <time_frame>40 weeks</time_frame>
    <description>PD markers: Plasma C4 (7α-hydroxy-4-cholesten-3-one)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: FGF19</measure>
    <time_frame>40 weeks</time_frame>
    <description>FGF19: Fibroblast Growth Factor 19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: BA</measure>
    <time_frame>40 weeks</time_frame>
    <description>Biles Acids (Plasma primary and secondary BAs)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Arm: EYP001a Dose A QD + NA daily (37 patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control Arm: Placebo + NA daily (12 patients)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EYP001a</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Are on stable NA therapy at least 12 months from the screening date (ETV or TDF)&#xD;
&#xD;
          -  Has virally suppressed CHB:&#xD;
&#xD;
        HBV DNA &lt;LLOQ and serum HBsAg &gt;100 IU/mL&#xD;
&#xD;
          -  Has liver imaging to screen for hepatocellular carcinoma or concomitant&#xD;
             pancreaticobiliary disease either in the prior 6 months or at screening.&#xD;
&#xD;
          -  Is not of childbearing potential or, if of childbearing potential, is not pregnant as&#xD;
             confirmed by a negative serum human chorionic gonadotropin test at screening and is&#xD;
             not planning a pregnancy during the course of the study.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Is an employee of a contract research organization (CRO), vendor, or Sponsor involved&#xD;
             with this study.&#xD;
&#xD;
          -  Has known hepatocellular carcinoma or pancreaticobiliary disease.&#xD;
&#xD;
          -  Neutropenia (defined by two confirmed values within screening period of &lt;1500/μL).&#xD;
&#xD;
          -  Has Gilbert syndrome.&#xD;
&#xD;
          -  Shows evidence of worsening liver function, defined as either a confirmed (two&#xD;
             assessments at least 3 days apart) increase &gt;2 ULN ALT or AST or an increase of &gt;1.5 ×&#xD;
             first assessed value of TBL or associated with clinical signs or symptoms of liver&#xD;
             impairment.&#xD;
&#xD;
          -  Has known or suspected non-CHB liver disease&#xD;
&#xD;
          -  History of cirrhosis or liver decompensation, including ascites, hepatic&#xD;
             encephalopathy, or presence of oesophageal varices.&#xD;
&#xD;
          -  Probable or possible F3 stage with a vibration controlled transient elastography&#xD;
             (VCTE). Patients with normal baseline ALT and VCTE &gt;8.8 kPa are excluded. Patients&#xD;
             with baseline ALT &gt;ULN (but &lt;2ULN per EC5) and who have VCTE &gt;10.5 kPa at baseline are&#xD;
             excluded 11.&#xD;
&#xD;
          -  Has known history of alcohol abuse or daily heavy alcohol consumption&#xD;
&#xD;
          -  Has clinically relevant immunosuppression, including, but not limited to,&#xD;
             immunodeficiency conditions such as common variable hypogammaglobulinemia.&#xD;
&#xD;
          -  Has used anti-HBV medications other than NAs within 90 days prior to screening.&#xD;
&#xD;
          -  Has any of the following exclusionary laboratory results at screening:&#xD;
&#xD;
               1. Estimated glomerular filtration rate &lt;60 mL/min/1.73 m2 (the Modification of Diet&#xD;
                  in Renal Disease formula).&#xD;
&#xD;
               2. Thyroid-stimulating hormone &gt;1.5× ULN or abnormal free triiodothyronine or free&#xD;
                  thyroxine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site KR04</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site KR03</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site KR02</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site KR01</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site PL06</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kielce, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site PL05</last_name>
    <role>Principal Investigator</role>
    <affiliation>Łódź, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site PL04</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zawiercie, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site PL03</last_name>
    <role>Principal Investigator</role>
    <affiliation>Warszawa, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site PL02</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lublin, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site PL01</last_name>
    <role>Principal Investigator</role>
    <affiliation>Białystok, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site AU04</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site AU03</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site AU02</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brisbane, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site AU01</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site HK01</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hong Kong, Hong Kong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site KR05</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seongnam, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site KR06</last_name>
    <role>Principal Investigator</role>
    <affiliation>Séoul, South Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ENYO PHARMA Investigative site KR07</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan, South Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site AU02</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site AU01</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site AU03</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site AU04</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site HK01</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site KR04</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site KR07</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site KR05</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site KR01</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site KR02</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site KR03</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site KR06</name>
      <address>
        <city>Séoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site PL01</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site PL06</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site PL02</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site PL03</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site PL04</name>
      <address>
        <city>Zawiercie</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENYO PHARMA Investigative site PL05</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

